Johns Hopkins
Mark Foundation, Johns Hopkins University Invest $10M in Cancer Immunotherapy Research
The funds will go toward new technologies, including genomics and imaging platforms, to identify why certain patients do and do not respond to cancer immunotherapy.
Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.
The company aims to release an initial tissue-based prognostic this year, with a less-invasive sponge-sampling version for screening high-risk individuals to follow in 2023.
Johns Hopkins researchers have developed a single-cell, multispectral imaging platform called AstroPath for precise pathological analysis of cancer specimens.
US, Canadian Researchers Partner to ID Biomarkers Predictive of Pancreatic Cancer Treatment
The project will involve molecular profiling of patients in a randomized trial and creating patient-derived organoids for personalized drug screening.